SIGA Technologies, Inc.

As of October 3, 2025, SIGA Technologies, Inc. has a mildly bullish trend with positive momentum indicated by MACD and moving averages, despite mixed signals from KST and a mildly bearish OBV, while year-to-date it has outperformed the S&P 500 but underperformed over the past three years.

As of August 6, 2025, SIGA Technologies, Inc. has a bullish technical trend supported by positive MACD and moving averages, outperforming the S&P 500 year-to-date with a 47.59% return, though it has underperformed over longer periods.

As of June 30, 2025, SIGA Technologies, Inc. is considered an attractive investment due to its low P/E ratio of 9, favorable EV to EBITDA of 4.72, strong ROCE of 103.73%, and a year-to-date return of 47.59%, outperforming the S&P 500.

As of March 11, 2025, SIGA Technologies, Inc. is considered attractive due to its undervalued status, with a P/E ratio of 9, significantly lower than the industry average, and strong operational efficiency indicated by a ROCE of 103.73% and ROE of 22.45%.

As of May 9, 2025, SIGA Technologies, Inc. is in a mildly bearish trend, influenced by daily moving averages and monthly MACD signals, despite some mildly bullish indicators on the weekly timeframe.

As of March 2022, the management team of SIGA Technologies, Inc. includes Dr. Eric Rose (Chairman), Dr. Phillip Gomez (CEO), and several independent directors: Mr. Julian Nemirovsky, Mr. James Antal, Mr. Thomas Constance, Ms. Julie Kane, and Mr. Joseph Marshall. They oversee the company's operations and strategic direction.

SIGA Technologies, Inc. is a pharmaceutical company focused on health security, primarily developing treatments for smallpox. As of March 2025, it reported net sales of $7 million and has a market cap of $450.08 million.

As of Jun 18, SIGA Technologies, Inc. has a market capitalization of 450.08 million, with net sales of 120.33 million and a net profit of 48.52 million over the latest four quarters.